tetano
Editor, Senior Moderator
Glob Heart
. 2022 Jan 12;17(1):2.
doi: 10.5334/gh.1037. eCollection 2022.
Cardiac Manifestations in Patients with COVID-19: A Scoping Review
Sasha Peiris[SUP] 1 2 [/SUP], Pedro Ordunez[SUP] 3 [/SUP], Donald DiPette[SUP] 4 [/SUP], Raj Padwal[SUP] 5 [/SUP], Pierre Ambrosi[SUP] 6 [/SUP], Joao Toledo[SUP] 1 2 [/SUP], Victoria Stanford[SUP] 7 [/SUP], Thiago Lisboa[SUP] 8 [/SUP], Sylvain Aldighieri[SUP] 1 2 [/SUP], Ludovic Reveiz[SUP] 1 7 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19), commonly affects the lungs, but the involvement of other organs, particularly the heart, is highly prevalent as has been reported in several studies. The overall aim of this review was to provide an in-depth description of the available literature related to the cardiac system and COVID-19 infection. It focuses on type and the frequency of cardiac manifestations, clinical parameters and cardiac biomarkers that support the prognosis of COVID-19 patients, and the cardiac adverse events and outcomes related to pharmacotherapy.
Methods: A scoping review was conducted searching Embase, PubMed, Epistomonikos, Medrxiv, BioRxiv databases, up to November 2020, for systematic reviews relevant to cardiac manifestations in adult COVID-19 patients. Relevant articles were screened and extracted to summarize key outcomes and findings.
Results: A total of 63 systematic reviews met the inclusion criteria. The overall frequency of acute cardiac injury ranged from 15% to 33% in the reporting studies. The main cardiac complications were arrhythmias (3.1% to 6.9% in non-severe patients, 33.0% to 48.0% in severe disease), acute coronary syndromes (6% to 33% in severe disease), and myocarditis. Most studies found no association with the use of Renin-angiotensin-aldosterone system inhibitors (RAASI) with COVID-19 outcomes such as susceptibility to infection, hospitalization, severity, and mortality.
Conclusion: This study provided an overview of the several cardiac complications associated with Covid-19. Cardiac injury, arrhythmias, myocarditis, cardiac failure, and acute coronary syndrome, are prevalent and clinically significant and associated with COVID-19 disease severity and mortality. Other studies are needed to clearly identify what is the part of viral heart infection and what is the part of cardiac injury secondary to acute respiratory failure and inflammation. In the therapeutic field, these systematic reviews gave heterogenous results. This underlines the importance of randomized trials to determine the right therapeutic approach.
Keywords: COVID-19; Complications; Heart; Heart Diseases; Review.
. 2022 Jan 12;17(1):2.
doi: 10.5334/gh.1037. eCollection 2022.
Cardiac Manifestations in Patients with COVID-19: A Scoping Review
Sasha Peiris[SUP] 1 2 [/SUP], Pedro Ordunez[SUP] 3 [/SUP], Donald DiPette[SUP] 4 [/SUP], Raj Padwal[SUP] 5 [/SUP], Pierre Ambrosi[SUP] 6 [/SUP], Joao Toledo[SUP] 1 2 [/SUP], Victoria Stanford[SUP] 7 [/SUP], Thiago Lisboa[SUP] 8 [/SUP], Sylvain Aldighieri[SUP] 1 2 [/SUP], Ludovic Reveiz[SUP] 1 7 [/SUP]
Affiliations
- PMID: 35174043
- PMCID: PMC8757387
- DOI: 10.5334/gh.1037
Abstract
Background: Coronavirus disease 2019 (COVID-19), commonly affects the lungs, but the involvement of other organs, particularly the heart, is highly prevalent as has been reported in several studies. The overall aim of this review was to provide an in-depth description of the available literature related to the cardiac system and COVID-19 infection. It focuses on type and the frequency of cardiac manifestations, clinical parameters and cardiac biomarkers that support the prognosis of COVID-19 patients, and the cardiac adverse events and outcomes related to pharmacotherapy.
Methods: A scoping review was conducted searching Embase, PubMed, Epistomonikos, Medrxiv, BioRxiv databases, up to November 2020, for systematic reviews relevant to cardiac manifestations in adult COVID-19 patients. Relevant articles were screened and extracted to summarize key outcomes and findings.
Results: A total of 63 systematic reviews met the inclusion criteria. The overall frequency of acute cardiac injury ranged from 15% to 33% in the reporting studies. The main cardiac complications were arrhythmias (3.1% to 6.9% in non-severe patients, 33.0% to 48.0% in severe disease), acute coronary syndromes (6% to 33% in severe disease), and myocarditis. Most studies found no association with the use of Renin-angiotensin-aldosterone system inhibitors (RAASI) with COVID-19 outcomes such as susceptibility to infection, hospitalization, severity, and mortality.
Conclusion: This study provided an overview of the several cardiac complications associated with Covid-19. Cardiac injury, arrhythmias, myocarditis, cardiac failure, and acute coronary syndrome, are prevalent and clinically significant and associated with COVID-19 disease severity and mortality. Other studies are needed to clearly identify what is the part of viral heart infection and what is the part of cardiac injury secondary to acute respiratory failure and inflammation. In the therapeutic field, these systematic reviews gave heterogenous results. This underlines the importance of randomized trials to determine the right therapeutic approach.
Keywords: COVID-19; Complications; Heart; Heart Diseases; Review.